Skip to content

Melanoma/Skin Cancer Health Center

Font Size

Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (05 / 16 / 2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Melanoma

Recommended Related to Melanoma/Skin Cancer

Understanding Skin Cancer -- the Basics

Skin cancers involve abnormal cell changes in the outer layer of skin. It is by far the most common cancer in the world, accounting for 75% of all cancer diagnoses. Most cases are cured, but the disease is a major health concern because it affects so many people. The incidence of skin cancer is rising, even though most cases could be prevented by limiting the skin's exposure to ultraviolet radiation. Skin cancer is about three times more common in men than in women, and the...

Read the Understanding Skin Cancer -- the Basics article > >

Added Risk Factors as a new subsection.

Cellular and Molecular Classification of Melanoma

Revised text to state that identification of activating mutations in the mitogen-activated protein (MAP) kinase pathway has led to the definition of molecular subtypes of melanoma and provided potential drug targets.

Treatment Option Overview

Revised text to state that prospective, randomized, controlled trials with both agents have not shown an increase in overall survival (OS) when compared with observation (cited Kirkwood et al. and Eggermont et al. as references 9 and 10, respectively.) Also added text about therapies that have impacted OS in patients with recurrent or metastatic disease that are now being tested as adjuvant therapy in clinical trials, including NCT01274338, NCT01667419, and NCT01682083.

Added text to state that these single agents are rarely curative, but the trials that incorporate these agents are testing combinations in an attempt to prevent development of drug resistance. Also added text about clinical trials that are testing targeted therapies in the smaller patient subsets.

Stage III Melanoma

Added text to state that prospective, randomized, multicenter treatment trials have demonstrated that high-dose interferon alpha-2b and pegylated interferon do not improve OS and agents that have demonstrated improved OS in patients with recurrent or metastatic disease are now being tested in clinical trials of adjuvant therapy in patients at high risk for relapse after surgical resection of tumor. These trials include: NCT01274338, NCT01667419, and NCT01682083.

Stage IV and Recurrent Melanoma

Added text to include checkpoint inhibitors in the treatment options list.

Revised text to state that although melanoma that has spread to distant sites is rarely curable, two approaches have demonstrated clinical benefit by prolonging OS in randomized trials: immunotherapy and inhibition of the MAP kinase pathway, adding that both ipilimumab and vemurafenib were approved by the U.S. Food and Drug Administration in 2011. Also added that although neither appears to be curative when used as a single agent, clinical trials are currently testing combinations of these and similar agents to prevent the development of resistance; additionally, ipilimumab and vemurafenib are available to newly diagnosed and previously treated patients.

    Next Article:

    Today on WebMD

    Malignant melanoma
    About 40-50 percent of those who live to be 65 may get it. Here’s how to spot early.
    Woman checking out tan lines
    There’s a dark side to that strive for beauty. See them here.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
    12 Ways to Protect Your Skin from Melanoma
    precancerous lesions slideshow
    Do You Know Your Melanoma ABCs
    15 Cancer Symptoms Men Ignore
    screening tests for men
    Vitamin D
    Is That Mole Skin Cancer
    Brilliant sun rays

    WebMD Special Sections